Serous Endometrial Cancers That Mimic Endometrioid Adenocarcinomas
- 1 December 2004
- journal article
- research article
- Published by Wolters Kluwer Health in The American Journal of Surgical Pathology
- Vol. 28 (12) , 1568-1578
- https://doi.org/10.1097/00000478-200412000-00004
Abstract
Background: Uterine serous carcinomas (USCs) can exhibit an architecturally well-differentiated tubuloglandular morphology with or without an accompanying papillary growth pattern. These features make it difficult to distinguish USCs from endometrial endometrioid carcinomas (EECs). Given the aggressive behavior of USC, compared with EEC, and differences in management, it is important to correctly classify endometrial carcinomas that exhibit a tubuloglandular architecture with high nuclear grade. We sought an immunohistochemical panel to minimize subjectivity in the distinction of USC from EEC. Materials and Methods: We identified 8 problematic endometrial cancers, exhibiting a tubuloglandular growth pattern and high nuclear grade, whose classification as EEC or USC was debated or resulted in disagreement. We selected 13 cases of International Federation of Gynecology and Obstetrics (FIGO) grade 2 EEC and 16 cases of USC as controls. An immunohistochemical panel, including p53, β-catenin, cyclin D1, estrogen receptor (ER), progesterone receptor (PR), and PTEN, was evaluated. Results: As a group, the clinical features and immunoprofile of the study cases resembled those of the serous controls. The study cases expressed p53, β-catenin, cyclin D1, and ER and PR, and showed loss of PTEN in 75%, 12.5%, 0%, 37.5%, 37.5%, and 12.5% of cases, respectively. p53, β-catenin, cyclin D1, ER and PR expression, and PTEN loss were seen in 87.5%, 0%, 19%, 31%, 12%, and 0% of the serous controls and in 7%, 70%, 54%, 92%, 92%, and 61.5% of the endometrioid controls, respectively. The combination of lack of p53 expression, positive PR expression, and loss of PTEN best distinguished between EEC and USC using discriminant analysis (multivariate P = 0.008, <0.001, and 0.05, respectively). Conclusion: In endometrial carcinomas exhibiting high nuclear grade and low architectural grade, using a panel of immunohistochemical stains may facilitate the distinction of USC from EEC. Our clinical and immunohistochemical data also support the concept that there is a group of endometrial adenocarcinomas composed of tubular glands that are indeed serous carcinomas.Keywords
This publication has 30 references indexed in Scilit:
- β-Catenin and E-Cadherin Expression Patterns in High-Grade Endometrial Carcinoma Are Associated with Histological SubtypeLaboratory Investigation, 2002
- Markers of Proliferative Activity Are Predictors of Patient Outcome for Low-Grade Endometrioid Adenocarcinoma But Not Papillary Serous Carcinoma of EndometriumLaboratory Investigation, 2002
- Extended Surgical Staging for Uterine Papillary Serous Carcinoma: Survival Outcome of Locoregional (Stage I–III) DiseaseGynecologic Oncology, 2001
- p27 and Cyclin D1 Abnormalities in Uterine Papillary Serous CarcinomaGynecologic Oncology, 2000
- FIGO staging of gynecologic cancerInternational Journal of Gynecology & Obstetrics, 1999
- PTENMutations in Endometrial Cancers with 10q LOH: Additional Evidence for the Involvement of Multiple Tumor SuppressorsGynecologic Oncology, 1998
- Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancersNature Genetics, 1997
- Papillary Carcinoma of the EndometriumInternational Journal of Gynecological Pathology, 1996
- Uterine Papillary Serous CarcinomaObstetrical & Gynecological Survey, 1991
- Uterine papillary serous carcinomaThe American Journal of Surgical Pathology, 1982